Peringatan Keamanan

Patients experiencing an overdose may present with shock, cyanosis, and coma.A204053 Treat patients with symptomatic and supportive measures which may include administration of fluids, exchange transfusions, and administration of dopamine.A204053

Chloramphenicol succinate

DB07565

small molecule approved

Deskripsi

Chloramphenicol succinate is an ester prodrug of chloramphenicol.A192987 Chloramphenicol is a bacteriostatic antibiotic.A204065 Use of chloramphenicol succinate and chloramphenicol has decreased due to the risk of potentially fatal blood dyscrasias.L14174

Chloramphenicol succinate was granted FDA approval on 20 February 1959.L12711

Struktur Molekul 2D

Berat 423.202
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half life of chloramphenicol succinate in patients with normal renal and hepatic function is 0.6-2.7h.[A192987]
Volume Distribusi Chloramphenicol succinate has a volume of distribution of 0.2-3.1L/kg.[A192987]
Klirens (Clearance) Chloramphenicol succinate's total clearance is 530-540mL/min in patients with normal renal and hepatic function, and 354mL/min in patients with renal or hepatic dysfunction.[A192987] Chloramphenicol succinate's renal clearance is 222-260mL/min in patients with normal renal and hepatic function, and 66mL/min in patients with renal or hepatic dysfunction.[A192987]

Absorpsi

Chloramphenicol succinate has a high degree of interpatient variability, with a Tmax of 18 minutes to 3 hours.A192987 A 1g oral chloramphenicol succinate dose every 6-8 hours reaches a mean Cmax of 11.2µg/mL with a Tmax of 1 hour.L14174

Metabolisme

Chloramphenicol succinate is hydrolyzed to chloramphenicol.A204047 The propane-diol moiety of chloramphenicol can be metabolised through a number of pathways including glucuronidation, sulfate conjugation, phosphorylation, acetylation, and oxidation.A204056 The dichloroacetate moiety can be metabolised through hydrolysis of the amide group and dechlorination.A204056 The nitro functional group can also be metabolised to an aryl amine and aryl amide metabolite.A204056

Rute Eliminasi

6-80% of chloramphenicol succinate is eliminated unchanged in the urine, though this is highly variable between patients.A192987 On average, 30% of chloramphenicol succinate is eliminated unchanged in the urine and 10% is eliminated as the active chloramphenicol in the urine.A192987

Interaksi Obat

53 Data
BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Chloramphenicol succinate.
Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Chloramphenicol succinate.
Dicoumarol The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Dicoumarol.
Phenindione The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Phenindione.
Warfarin The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Warfarin.
Phenprocoumon The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Phenprocoumon.
Acenocoumarol The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Coumarin.
(R)-warfarin The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Fluindione.
Clorindione The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Clorindione.
Diphenadione The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Diphenadione.
Tioclomarol The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with Tioclomarol.
(S)-Warfarin The risk or severity of bleeding can be increased when Chloramphenicol succinate is combined with (S)-Warfarin.
Vibrio cholerae CVD 103-HgR strain live antigen The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Chloramphenicol succinate.
Estetrol The therapeutic efficacy of Estetrol can be decreased when used in combination with Chloramphenicol succinate.
Lidocaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Lidocaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Ropivacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Bupivacaine.
Cinchocaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Cinchocaine.
Dyclonine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Dyclonine.
Procaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Procaine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Prilocaine.
Proparacaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Proparacaine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Meloxicam.
Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Oxybuprocaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Cocaine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Mepivacaine.
Levobupivacaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Levobupivacaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Diphenhydramine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Benzocaine.
Chloroprocaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Chloroprocaine.
Phenol The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Phenol.
Tetrodotoxin The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Tetrodotoxin.
Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Benzyl alcohol.
Capsaicin The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Capsaicin.
Etidocaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Etidocaine.
Articaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Articaine.
Tetracaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Tetracaine.
Propoxycaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Propoxycaine.
Pramocaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Pramocaine.
Butamben The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Butamben.
Butacaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Butacaine.
Oxetacaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Oxetacaine.
Ethyl chloride The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Ethyl chloride.
Butanilicaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Butanilicaine.
Metabutethamine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Metabutethamine.
Quinisocaine The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Quinisocaine.
Cisatracurium Chloramphenicol succinate may increase the neuromuscular blocking activities of Cisatracurium.
Ambroxol The risk or severity of methemoglobinemia can be increased when Chloramphenicol succinate is combined with Ambroxol.
Fecal microbiota The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Chloramphenicol succinate.

Target Protein

Dr hemagglutinin structural subunit draA

Referensi & Sumber

Artikel (PubMed)
  • PMID: 22155764
    Borde AS, Karlsson EM, Andersson K, Bjorhall K, Lennernas H, Abrahamsson B: Assessment of enzymatic prodrug stability in human, dog and simulated intestinal fluids. Eur J Pharm Biopharm. 2012 Apr;80(3):630-7. doi: 10.1016/j.ejpb.2011.11.011. Epub 2011 Dec 4.
  • PMID: 6375931
    Ambrose PJ: Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clin Pharmacokinet. 1984 May-Jun;9(3):222-38. doi: 10.2165/00003088-198409030-00004.
  • PMID: 1242145
    Thompson WL, Anderson SE, Lipsky JJ, Lietman PS: Letter: Overdoses of chloramphenicol. JAMA. 1975 Oct 13;234(2):149-50.
  • PMID: 7875065
    Bories GF, Cravedi JP: Metabolism of chloramphenicol: a story of nearly 50 years. Drug Metab Rev. 1994;26(4):767-83. doi: 10.3109/03602539408998326.
  • PMID: 31613458
    Loree J, Lappin SL: Bacteriostatic Antibiotics .
  • PMID: -
    Jardetzky O: Studies on the Mechanism of Action of Chloramphenicol The Journal of Biological Chemistry. 1963 July;238(7):2498-2508.
  • PMID: 23650345
    Schifano JM, Edifor R, Sharp JD, Ouyang M, Konkimalla A, Husson RN, Woychik NA: Mycobacterial toxin MazF-mt6 inhibits translation through cleavage of 23S rRNA at the ribosomal A site. Proc Natl Acad Sci U S A. 2013 May 21;110(21):8501-6. doi: 10.1073/pnas.1222031110. Epub 2013 May 6.
  • PMID: 23118672
    Wiest DB, Cochran JB, Tecklenburg FW: Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess. J Pediatr Pharmacol Ther. 2012 Apr;17(2):182-8. doi: 10.5863/1551-6776-17.2.182.

Contoh Produk & Brand

Produk: 4 • International brands: 0
Produk
  • Chloramphenicol Sodium Succinate
    Injection, powder, lyophilized, for solution • 1 g/10mL • Intravenous • US • Generic • Approved
  • Chloramphenicol Sodium Succinate
    Injection, powder, lyophilized, for solution • 1 g/10mL • Intravenous • US • Generic • Approved
  • Chloromycetin Sodium Succinate
    Injection • 100 mg/1mL • Intravenous • US • Approved
  • Chloromycetin Succinate Injection
    Powder, for solution • 1 g / vial • Intravenous • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul